{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:54Z","timestamp":1793367354390,"version":"4.5.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"BTG Specialty Pharmaceuticals"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>High-dose methotrexate (HDMTX) is administered for the treatment of some cancers. HDMTX is usually safe but may crystallize in renal tubules causing acute kidney injury (AKI). Consequently, MTX elimination is delayed, resulting in a severe and life-threatening condition. No studies have been published about the impact of MTX toxicity in Spain. This study aims to estimate the incidence and management of MTX delayed elimination and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A two-round Delphi study was performed to reach consensus between 10 medical experts on haemato-oncology and paediatric oncology with experience in the management of HDMTX treated patients from leading Spanish hospitals. An online questionnaire was developed based on national and international guidelines and previous evidence regarding HDMTX-related toxicity. Consensus was established at 80% agreement. Median and interquartile ranges were calculated, and incidence data were extrapolated to the Spanish general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 1.475 patients estimated to receive HDMTX treatment annually in Spain, 27.5% present MTX delayed elimination and 11.6% develop HDMTX-induced AKI (35.4% with severe systemic toxicities (&gt;grade 3) and 18.8% develop chronic renal disease). Mortality is estimated in 4.2%. Immuno-enzymatic assay is used in most of the hospitals (90%) for MTX serum level monitoring. All experts use increased supportive care and high leucovorin as first-line treatment. Available treatments in experts\u2019 hospitals in case toxicity persists are haemodialysis (90% of hospitals), glucarpidase (60%) and hemofiltration (50%). Most prevalent non-renal systemic toxicities are haematologic and mucositis (21\u201340% of patients). Patients with HDMTX-induced AKI require from intensive care (5% of patients), more than 3 sessions and 4 days of dialysis, and about 8.5 days of hospitalization (non-ICU patients) and 12 days in case of patients requiring ICU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results are the first evidence regarding HDMTX-induced AKI in Spain. Incidence and mortality results are in line with previous studies. Clinical management is based on preventive measures and the treatment depend on the availability in the hospital. The need for effective, safe and rapid treatment for the reduction of MTX toxic levels and the improvement of monitoring methods were noted by experts as urgent needs. Further observational studies to validate these results would be needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221079568","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T08:35:41Z","timestamp":1644568541000},"page":"794-801","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study"],"prefix":"10.1177","volume":"29","author":[{"given":"Luis","family":"Gros","sequence":"first","affiliation":[{"name":"Servicio de Oncolog\u00eda y Hematolog\u00eda Pedi\u00e1tricas, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-5678","authenticated-orcid":false,"given":"Alicia","family":"Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Hematolog\u00eda y Hemoterapia, Hospital Universitario Infanta Sof\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Cabero-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Departamento de Hematolog\u00eda y Hemoterapia, Hospital Universitario de Salamanca (HUS), Instituto Biom\u00e9dico de Salamanca (IBSAL), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Dom\u00ednguez-Pinilla","sequence":"additional","affiliation":[{"name":"Unidad de Hemato-Oncolog\u00eda Pedi\u00e1trica, Complejo Hospitalario de Toledo, Toledo, Spain; Unidad de Hemato-Oncolog\u00eda Pedi\u00e1trica, Hospital 12 de Octubre, Madrid. Instituto de Investigaci\u00f3n i\u2009+\u200912, Hospital 12 de Octubre, Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"de la Fuente","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, MD Anderson, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gonz\u00e1lez-Barca","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u2019Oncologia, Hematology Department, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Tasso","sequence":"additional","affiliation":[{"name":"Unidad de Oncolog\u00eda y Hematolog\u00eda Pedi\u00e1trica, Hospital General Universitario de Alicante, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Torrent","sequence":"additional","affiliation":[{"name":"Servicio de Onco-hematolog\u00eda pedi\u00e1trica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gallardo","sequence":"additional","affiliation":[{"name":"BTG Specialty Pharmaceuticals, Llandysul, UK of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"del Cerro","sequence":"additional","affiliation":[{"name":"Omakase Consulting S.L., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Gir\u00f3-Perafita","sequence":"additional","affiliation":[{"name":"Omakase Consulting S.L., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-2550","authenticated-orcid":false,"given":"Xavier","family":"Badia","sequence":"additional","affiliation":[{"name":"Omakase Consulting S.L., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"bibr1-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw175"},{"key":"bibr2-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"bibr3-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw025"},{"key":"bibr4-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy310"},{"key":"bibr5-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I"},{"key":"bibr6-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1177\/2399369319827305"},{"key":"bibr7-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0243"},{"key":"bibr8-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164"},{"key":"bibr9-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694"},{"key":"bibr10-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107362"},{"key":"bibr11-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1007\/BF00548590"},{"key":"bibr12-10781552221079568","doi-asserted-by":"publisher","DOI":"10.2174\/1389200220666190806140844"},{"key":"bibr13-10781552221079568","first-page":"851","volume":"10","author":"Bacci G","year":"2003","journal-title":"Oncol Rep"},{"key":"bibr14-10781552221079568","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.840780"},{"key":"bibr15-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2479"},{"key":"bibr16-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27378"},{"key":"bibr17-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26395"},{"key":"bibr18-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-017-1420-y"},{"key":"bibr19-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602337"},{"key":"bibr20-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1007\/BF00625045"},{"key":"bibr21-10781552221079568","first-page":"745","volume":"61","author":"von Hoff D","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"bibr22-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20255"},{"key":"bibr23-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn503"},{"key":"bibr24-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.09.006"},{"key":"bibr25-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220946464"},{"key":"bibr26-10781552221079568","first-page":"655","volume":"38","author":"McMillan SS","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"bibr27-10781552221079568","first-page":"305","volume":"11","author":"Avella JR","year":"2016","journal-title":"Int J Dr Stud"},{"key":"bibr28-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2003.02537.x"},{"key":"bibr29-10781552221079568","unstructured":"SEHOP, PETHEMA.\n                      Tratamiento de la Leucemia Aguda Linfobl\u00e1stica de Nuevo Diagn\u00f3stico\n                      , https:\/\/www.sehh.es\/images\/stories\/recursos\/2014\/documentos\/guias\/LAL_SEHOP_PETHEMA_2013.pdf (2014, accessed 20 September 2021)."},{"key":"bibr30-10781552221079568","unstructured":"GELTAMO. Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia.\n                      Gu\u00eda de GELTAMO para diagn\u00f3stico, prevenci\u00f3n y manejo terap\u00e9utico de la afectaci\u00f3n del sistema nervioso central en pacientes con linfoma B difuso de c\u00e9lula grande\n                      , https:\/\/www.geltamo.com\/images\/stories\/recursos\/2016\/PCSNC_LDCGB.pdf (2017, accessed 20 September 2021)."},{"key":"bibr31-10781552221079568","unstructured":"PETHEMA, SEHH.\n                      Protocolo para el tratamiento de la leucemia aguda linfobl\u00e1stica de alto riesgo BCR\/ABL negativa en adultos\n                      , https:\/\/www.sehh.es\/images\/stories\/recursos\/pethema\/protocolos\/LAL\/LAL_AR_2011version-5-7-2013.pdf (2011, accessed 20 September 2021)."},{"key":"bibr32-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/42.1.39"},{"key":"bibr33-10781552221079568","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645120-00007"},{"key":"bibr34-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0394-3"},{"key":"bibr35-10781552221079568","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1957"},{"key":"bibr36-10781552221079568","first-page":"317","volume":"41","author":"Aguilar-Salmer\u00f3n R","year":"2017","journal-title":"Farm Hosp"},{"key":"bibr37-10781552221079568","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02560319"},{"key":"bibr38-10781552221079568","first-page":"21","volume":"2","author":"Sonis S","year":"2004","journal-title":"J Support Oncol"},{"key":"bibr39-10781552221079568","volume-title":"El m\u00e9todo delphi : una t\u00e9cnica de previsi\u00f3n para la incertidumbre","author":"Landeta J","year":"1999"},{"key":"bibr40-10781552221079568","volume":"7","author":"Ruiz Olabu\u00e9naga J","year":"1989","journal-title":"Sociolog\u00eda"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221079568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221079568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221079568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:39Z","timestamp":1777688799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221079568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/10781552221079568"],"URL":"https:\/\/doi.org\/10.1177\/10781552221079568","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]}}}